COMP <GO>
ONC vs MRK // FREE CASH FLOW YIELD
BeOne Medicines Ltd. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ONC 5
— MRK 10
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
fcf-yield
2.23%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | 74.80% | +12.70 | ONC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 20.70% | -10.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 63.9x | 15.3x | +48.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.23% | 3.42% | -1.19 | MRK | /fcf-yield <GO> |
| Operating Margin | 8.40% | 34.30% | -25.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 28.10% | -22.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 1.30% | +38.90 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 5.19 | +1.49 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.7 | 56.9 | -4.18 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.92 | +0.06 | ONC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 123.6x | 18.4x | +105.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $361.02B | -$318.77B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | MRK REV | ONC GROSS % | MRK GROSS % | ONC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $65.01B | 87.5% | 74.8% | $941.7M | $12.36B |
| FY 2024 | $3.81B | $64.17B | 84.4% | 76.3% | -$633.3M | $18.10B |
| FY 2023 | $2.46B | $60.12B | 44.0% | 44.0% | -$1.27B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
MRK // BETA 0.92